PLAAT3

Across TCGA pan-cancer cohorts, PLAAT3 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated PLAAT3 data layer compared with 22 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PLAAT3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PLAAT3 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

LUAD, OV, and PDAC are the cancer types where PLAAT3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	II,III,IV	1.000	0.220	.014	17	view →
OV	DFS	Median	All	0.411	1.000	.028	8	view →
PDAC	OS	Median	IV	0.643	0.836	.038	3	view →
GBM	OS	Quartile	All	0.227	0.604	.047	2	view →
LSCC	DFS	Median	II,III,IV	1.000	0.571	.030	2	view →
HNSC	DFS	Median	IV	0.745	0.259	.033	2	view →
CCRCC	OS	Tertile	III,IV	1.000	0.374	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

PLAAT3–LUAD (DFS)

Open the LUAD breakdown →